Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector.
The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer and share data with their healthcare team.
Get the full story at our sister site, Drug Delivery Business News.
The post Bayer wins FDA nod for connected MS auto-injector appeared first on MassDevice.
from MassDevice http://ift.tt/2qAzraV
Cap comentari:
Publica un comentari a l'entrada